RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks [Yahoo! Finance]
Rallybio Corporation (RLYB)
Company Research
Source: Yahoo! Finance
The company decided to stop the development of RLYB212 after pharmacokinetic (PK) data from a phase II study showed that treatment with the candidate failed to achieve predicted target concentrations of 6 ng/mL to 10, as well as the minimum target concentration required for efficacy of 3 ng/mL. The phase II dose confirmation study evaluated the PK and safety of RLYB212 in pregnant women who are at higher risk for HPA-1a alloimmunization and FNAIT. RLYB212, a novel human monoclonal anti-HPA-1a antibody, was being developed to prevent pregnant individuals from alloimmunizing, which curbs the risk of FNAIT and its potentially devastating consequences in their fetuses and newborns. Year to date, shares of Rallybio have plunged 74% compared with the industry's decline of 8.9%. Image Source: Zacks Investment Research Following the setback related to RLYB212, the company is now focused on developing its lead candidate, RLYB116, a differentiated C5 inhibitor, for the treatment of c
Show less
Read more
Impact Snapshot
Event Time:
RLYB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLYB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLYB alerts
High impacting Rallybio Corporation news events
Weekly update
A roundup of the hottest topics
RLYB
News
- Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rallybio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire
- Rallybio (NASDAQ:RLYB) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RLYB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- Rallybio (NASDAQ:RLYB) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RLYB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
RLYB
Earnings
- 5/8/25 - In-Line
RLYB
Sec Filings
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- RLYB's page on the SEC website